The Relationship Between Serum E2 Level and Recurrence During Endocrine Therapy for Er Positive Pre-Menopausal Early Breast Cancer Patients

ABSTRACT Acquired endocrine therapy resistance is a significant clinical problem for breast cancer patients. In recent years, increasing attention has been paid to long noncoding RNA (lncRNA) as a critical modulator for cancer progression. Based on RNA-sequencing data of breast invasive carcinomas in The Cancer Genome Atlas database, we identified thymopoietin antisense transcript 1 (TMPO-AS1) as a functional lncRNA that significantly correlates with proliferative biomarkers. TMPO-AS1 positivity analyzed by in situ hybridization significantly correlates with poor prognosis of breast cancer patients. TMPO-AS1 expression was upregulated in endocrine therapy-resistant MCF-7 cells compared with levels in parental cells and was estrogen inducible. Gain and loss of TMPO-AS1 experiments showed that TMPO-AS1 promotes the proliferation and viability of estrogen receptor (ER)-positive breast cancer cells in vitro and in vivo. Global expression analysis using a microarray demonstrated that TMPO-AS1 is closely associated with the estrogen signaling pathway. TMPO-AS1 could positively regulate estrogen receptor 1 (ESR1) mRNA expression by stabilizing ESR1 mRNA through interaction with ESR1 mRNA. Enhanced expression of ESR1 mRNA by TMPO-AS1 could play a critical role in the proliferation of ER-positive breast cancer. Our findings provide a new insight into the understanding of molecular mechanisms underlying hormone-dependent breast cancer progression and endocrine resistance.

Download Full-text

Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy

The Breast ◽

10.1016/j.breast.2012.07.005 ◽

2012 ◽

Vol 21 (5) ◽

pp. 662-668 ◽

Cited By ~ 7

Author(s):

Mathilde S. Larsen ◽

Karsten Bjerre ◽

Anne E. Lykkesfeldt ◽

Anita Giobbie-Hurder ◽

Anne-Vibeke Lænkholm ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Endocrine Therapy ◽

Adjuvant Endocrine Therapy ◽

Breast Cancer Patients ◽

Er Positive ◽

Predicting Outcome ◽

Positive Breast Cancer

Download Full-text

Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer

Journal of Molecular Endocrinology ◽

10.1677/jme-08-0076 ◽

2008 ◽

Vol 42 (2) ◽

pp. 87-103 ◽

Cited By ~ 37

Author(s):

Sandra E Ghayad ◽

Julie A Vendrell ◽

Ivan Bieche ◽

Frédérique Spyratos ◽

Charles Dumontet ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Candidate Genes ◽

Endocrine Therapy ◽

Cell Lines ◽

Tamoxifen Treatment ◽

Cross Resistance ◽

Breast Cancer Patients ◽

Er Positive ◽

Positive Breast Cancer

Cross-resistance to molecules used in endocrine therapy is among the main challenges in the treatment of estrogen receptor-α (ERα) positive breast cancer. In this study, we used two different cell models of resistance to anti-estrogens: MVLN/CL6.7 cells and VP229/VP267 cells selected after exposure to tamoxifen respectively in vitro and in vivo to characterize a phenotype rarely observed, i.e. acquisition of cross-resistance to the pure ER antagonist fulvestrant. As MVLN/CL6.7 cells and VP229/VP267 cell lines are original and valuable models of cross-resistance to tamoxifen and fulvestrant, we examined candidate genes using a RTQ-PCR strategy to identify new biomarkers of endocrine resistance. Out of the 26 candidate genes tested, 19 displayed deregulation of expression at the basal level in at least one of the two resistant cell lines. Eight genes (TACC1, NOV, PTTG1, MAD2L1, BAK1, TGFB2, BIRC5, and CCNE2) were significantly overexpressed in samples from ER-positive breast cancer patients who relapsed after tamoxifen treatment (n=24) compared with samples from patients who did not (n=24). Five genes (TACC1, NOV, PTTG1, BAK1, and TGFB2) were correlated with significantly shorter relapse-free survival (univariate analysis). Finally, we identified TACC1 and a three-gene expression signature (TACC1, NOV, and PTTG1) as independent prognostic markers (multivariate analysis). Aberrant mRNA and protein levels of TACC1, NOV, and PTTG1 were also observed under tamoxifen and/or fulvestrant exposure in resistant CL6.7 cells compared with their respective control MVLN cells. In conclusion, our data identify TACC1, NOV, and PTTG1 as promising new markers that could be used in the clinical management of ER-positive breast cancer patients.

Download Full-text

The relationship between serum E2 levels and recurrence in premenopausal, ER-positive breast cancer patients: A retrospective study

Breast Disease ◽

10.3233/bd-170307 ◽

2018 ◽

Vol 37 (4) ◽

pp. 185-190 ◽

Cited By ~ 1

Author(s):

Haruko Takuwa ◽

Shigehira Saji ◽

Masahiro Takada ◽

Sachiko Takahara ◽

Akira Yamauchi

Keyword(s):

Breast Cancer ◽

Retrospective Study ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Er Positive ◽

The Relationship ◽

Positive Breast Cancer

Download Full-text

Impact of the EndoPredict-clin score on risk stratification in ER-positive, HER2-negative breast cancer after considering clinical guidelines.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.542 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. 542-542

Author(s):

Martin Filipits ◽

Peter Christian Dubsky ◽

Margaretha Rudas ◽

Jan C. Brase ◽

Ralf Kronenwett ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Cancer Patients ◽

Endocrine Therapy ◽

Clinical Guidelines ◽

Risk Groups ◽

Low Risk ◽

Breast Cancer Patients ◽

Free Survival ◽

Er Positive

542 Background: Many ER-positive, HER2-negative breast cancer patients are treated by adjuvant chemotherapy according to current clinical guidelines. We retrospectively assessed whether the combined gene expression/ clinicopathological EndoPredict-clin (EPclin) score improved the accuracy of risk classification in addition to considering clinical guidelines. Methods: Three clinical breast cancer guidelines (National Comprehensive Cancer Center Network (NCCN), German S3 and St. Gallen 2011), and the EPclin score - assessed by quantitative RT-PCR in formalin-fixed paraffin-embedded tissue - were used to assign risk groups in 1,702 ER-positive, HER2-negative breast cancer patients from two randomized phase III trials (Austrian Breast and Colorectal Cancer Study Group 6 and 8) treated with endocrine therapy only. Results: Although all analyzed clinical guidelines identified a low-risk group with improved metastasis-free survival, the overwhelming majority of all patients (81-94%) were classified as intermediate / high risk. In contrast to that, the EPclin classified only 37% of all patients as high risk and that stratification resulted in the best separation between low and high risk groups (p < 0.001, HR = 5.11 (3.48-7.51). Consequently, the majority of all patients deemed intermediate / high risk by the clinical guidelines was re-classified as low risk by the EPclin score. Kaplan Meier analyses demonstrated that the re-classified subgroups (47 to 57% of all patients) had an excellent 10-year metastasis-free survival of 95% comparable to the clinical assigned low-risk groups although encompassing a higher proportion of the trial patients. Conclusions: The EPclin score predicted distant recurrence more accurately than all three clinical guidelines and is especially useful to reclassify patients considered as intermediate / high risk by the guidelines. The data suggests that the EPclin score provides clinically useful prognostic information beyond common clinical guidelines and can be used to accurately identify the clinically relevant group of patients who are adequately and sufficiently treated with adjuvant endocrine therapy alone.

Download Full-text

ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy

OncoTargets and Therapy ◽

10.2147/ott.s142698 ◽

2017 ◽

Vol Volume 10 ◽

pp. 4859-4867 ◽

Cited By ~ 6

Author(s):

Fangbin Song ◽

Jianbing Zhang ◽

Shanbao Li ◽

Junyi Wu ◽

Tao Jin ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Cancer Patients ◽

Endocrine Therapy ◽

Late Recurrence ◽

Adjuvant Endocrine Therapy ◽

Breast Cancer Patients ◽

Er Positive ◽

Grade 3 ◽

Positive Breast Cancer

Download Full-text

Primary endocrine therapy vs chemotherapy in postmenopausal ER-positive breast cancer patients

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(06)80260-0 ◽

2006 ◽

Vol 4 (2) ◽

pp. 117

Author(s):

V. Semiglazov ◽

Kletsel ◽

E. Zhiltsova ◽

V. Ivanov ◽

G. Dashyan ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Endocrine Therapy ◽

Breast Cancer Patients ◽

Er Positive ◽

Primary Endocrine Therapy ◽

Positive Breast Cancer

Download Full-text

Research on the Relationship Between Self-Management Efficacy and Quality of Life for Breast Cancer Patients Receiving Endocrine Therapy

10.21203/rs.3.rs-1126991/v1 ◽

2022 ◽

Author(s):

Hongjie Yi ◽

Haoran Jiang ◽

Aiping Wang ◽

Wei Zong ◽

Yu Dong ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Cancer Patients ◽

Endocrine Therapy ◽

Influencing Factors ◽

The Self ◽

Self Management ◽

Breast Cancer Patients ◽

The Relationship

Abstract Purpose To investigate the status quo and relationship between self-management efficacy and quality of life (QOL) of patients with breast cancer undergoing endocrine therapy, and to explore the influencing factors of QOL. Methods The convenience sampling method was used to select 240 patients who received endocrine therapy after breast cancer surgery in the First Hospital of China Medical University, the self-designed general data questionnaire, self-management efficacy questionnaire for breast cancer patients with endocrine therapy and quality of life scale for breast cancer patients were used to investigate. The frequency, percentage, mean ± standard deviation were used to describe patients' self-management efficacy and quality of life. Pearson correlation analysis was used to analyze the relationship between self-management efficacy and quality of life, and univariate analysis and multiple stepwise regression were used to analyze the influencing factors of QOL. Results The scores of self-management efficacy and QOL of patients with breast cancer endocrine therapy were 125.21 ± 25.57 and 153.33 ± 19.31 respectively, which were at the middle level; self-management efficacy was significantly positively correlated with quality of life ( p < 0.01 ) ; multiple stepwise regression results showed that self-management efficacy, the number of physical symptoms, monthly family income and recurrence and metastasis were the influencing factors of QOL. Conclusion The self-management efficacy of endocrine therapy was positively correlated with QOL in breast cancer patients. The higher the self-management efficacy of endocrine therapy, the better QOL in breast cancer patients. Self-management efficacy is the main factor affecting the quality of life of breast cancer patients undergoing endocrine therapy. Improving the level of self-management efficacy can improve their quality of life.

Download Full-text

Comparing outcomes of neoadjuvant endocrine therapy versus chemotherapy in ER-positive breast cancer: Results from a prospective institutional database.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.581 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. 581-581 ◽

Cited By ~ 1

Author(s):

Nathalie LeVasseur ◽

Walter Yip ◽

Huaqi Li ◽

Kaylie Willems ◽

Caroline Illmann ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Endocrine Therapy ◽

Clinical Stage ◽

Breast Cancer Patients ◽

Long Term Outcomes ◽

Neoadjuvant Endocrine Therapy ◽

Er Positive ◽

Positive Breast Cancer

581 Background: While neoadjuvant chemotherapy (NACT) has been established as the standard of care for medically fit patients, there has been renewed interest in utilizing neoadjuvant endocrine therapy (NET) for the treatment of women with estrogen-receptor (ER) positive, HER-2 negative breast cancer. Rates of pCR are known to be low in this population, but there is inconsistent data regarding downstaging and long-term outcomes in a non-trial setting with NET vs NACT. Methods: A prospective institutional databaseof breast cancer patients treated with neoadjuvant therapy at the British Columbia Cancer Agency from 2012-2016 was analyzed to identify all medically fit patients with ER positive, HER2 negative breast cancer. Patients were then divided into two groups: those who received NET or NACT. Baseline characteristics were compared between groups. A matched analysis (age, stage and grade) was then performed to compare rates of downstaging, pCR and scores from a validated neoadjuvant therapy outcomes calculator (CPS+EG). Results: A total of 154 patients met eligibility criteria for this study. One hundred and six patients (69%) received NACT and 48 (31%) received NET. Women offered NACT were significantly younger (51 vs 64y, p < 0.001) than those offered endocrine therapy and presented with a higher clinical stage (LR 27.93, p = 0.002). According to multiple linear regression for downstaging, clinical stage followed by NACT were the most important predictors of downstaging. When matched for age, stage and grade, downstaging was significantly higher with NACT (31/48, 65%) as compared to NET (12/48, 25%), p < 0.001. Of these, 12.5% achieved pCR with NACT as compared to 2.1% with NET, LR 4.243, p = 0.039. No significant differences in CPS+EG scores were identified when comparing NACT to NET. Conclusions: Significantly higher rates of downstaging were achieved with NACT as compared to NET when patients were matched for age, stage and grade. Rates of pCR remain low for ER-positive breast cancer patients. Although not validated with the use of NET, CPS+EG scores predicting long-term outcomes were not significantly different with NET compared to NACT.

Download Full-text